Literature DB >> 11959578

Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia.

Pamela R Tessier1, Myo-Kyoung Kim, Wen Zhou, Dawei Xuan, Chonghua Li, Min Ye, Charles H Nightingale, David P Nicolau.   

Abstract

The pharmacodynamic profile of clarithromycin (CLR) was evaluated with a murine model of pneumonia. Eight Streptococcus pneumoniae isolates, including three macrolide-sensitive and five macrolide-resistant strains, were inoculated intratracheally into immunocompromised ICR mice as 10(8)-CFU bacterial suspensions. Orally administered CLR daily doses ranging from 5 to 600 mg/kg of body weight were given over 5 days, during which animal survival was monitored. The bacterial density in lung tissues was examined after 24 h of CLR treatment and in control groups. Pharmacokinetic analysis of CLR in mice demonstrated that the regimen of 150 mg/kg twice a day was representative of human pharmacokinetics and was used to compare the efficacy of CLR against sensitive and resistant S. pneumoniae strains. Immunocompetent CBA/J mice were also infected and treated as described above and evaluated for bacterial density and survival to assess the effect of the presence of leukocytes. All three pharmacodynamic parameters, the duration (percent) of the time that serum CLR concentrations remain above the MIC (%T>MIC), the ratio of the area under the concentration-time curve from 0 to 24 h (AUC(0-24)) to the MIC, and the ratio of the maximum concentration of drug in serum to the MIC, were found to be closely correlated to CLR bacterial efficacy (P < 0.001). Furthermore, all parameters had close correlation to bacterial density (r(2) = 0.72 to 0.82), median survival (r(2) = 0.93 to 0.94), and total percent survival (r(2) = 0.91 to 0.92). These in vivo data suggest that the bacterial activity of CLR is closely correlated with all three parameters over a wide range of exposures and, as a consequence of parameter interdependency, AUC(0-24)/MIC is the most reasonable predictor of antibiotic efficacy. In this neutropenic pneumonia model, CLR was less efficacious against S. pneumoniae strains for which MICs were >or=4 microg/ml. However, the presence of leukocytes in the immunocompetent mice resulted in improved bactericidal activity, relative to that in the neutropenic animals, despite an MIC of 4 microg/ml.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11959578      PMCID: PMC127127          DOI: 10.1128/AAC.46.5.1425-1434.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

Review 1.  Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.

Authors:  M C Roberts; J Sutcliffe; P Courvalin; L B Jensen; J Rood; H Seppala
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Relationship between capsular type, penicillin susceptibility, and virulence of human Streptococcus pneumoniae isolates in mice.

Authors:  E Azoulay-Dupuis; V Rieux; M Muffat-Joly; J P Bédos; E Vallée; C Rivier; R Isturiz; C Carbon; P Moine
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

3.  Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.

Authors:  G Woodnutt; V Berry
Journal:  Antimicrob Agents Chemother       Date:  1999-01       Impact factor: 5.191

Review 4.  Comparison of bacteriologic eradication of Streptococcus pneumoniae by clarithromycin and reports of increased antimicrobial resistance.

Authors:  M H Gotfried
Journal:  Clin Ther       Date:  2000-01       Impact factor: 3.393

5.  In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.

Authors:  D Andes; W A Craig
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

Review 6.  Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen.

Authors:  P Periti; T Mazzei
Journal:  J Chemother       Date:  1999-02       Impact factor: 1.714

7.  In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model.

Authors:  P Moine; E Vallée; E Azoulay-Dupuis; P Bourget; J P Bédos; J Bauchet; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

8.  Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia.

Authors:  B Veber; E Vallée; J M Desmonts; J J Pocidalo; E Azoulay-Dupuis
Journal:  J Antimicrob Chemother       Date:  1993-09       Impact factor: 5.790

Review 9.  Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens.

Authors:  C Carbon
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

10.  Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and ceruroxime axetil against Streptococcus pneumoniae.

Authors:  M K Lacy; R C Owens; X Xu; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Int J Antimicrob Agents       Date:  1998-11       Impact factor: 5.283

View more
  24 in total

1.  Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model.

Authors:  Pamela R Tessier; Holly M Mattoes; Prachi K Dandekar; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis.

Authors:  Friederike Traunmüller; Markus Zeitlinger; Petra Zeleny; Markus Müller; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

3.  Antimicrobial therapy for bacillus anthracis-induced polymicrobial infection in (60)Co gamma-irradiated mice.

Authors:  Thomas B Elliott; Itzhak Brook; Rita A Harding; S Samy Bouhaouala; Michael O Shoemaker; Gregory B Knudson
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.

Authors:  Robert D Hardy; Ana Maria Rios; Susana Chavez-Bueno; Hasan S Jafri; Jeanine Hatfield; Beverly B Rogers; George H McCracken; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

Review 5.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

6.  High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease.

Authors:  Till F Omansen; Deepak Almeida; Paul J Converse; Si-Yang Li; Jin Lee; Ymkje Stienstra; Tjip van der Werf; Jacques H Grosset; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

7.  Efficacy of clarithromycin against experimentally induced pneumonia caused by clarithromycin-resistant Haemophilus influenzae in mice.

Authors:  Shigeki Nakamura; Katsunori Yanagihara; Nobuko Araki; Koichi Yamada; Yoshitomo Morinaga; Koichi Izumikawa; Masafumi Seki; Hiroshi Kakeya; Yoshihiro Yamamoto; Shimeru Kamihira; Shigeru Kohno
Journal:  Antimicrob Agents Chemother       Date:  2009-11-30       Impact factor: 5.191

8.  What Is the Clinical Impact of Macrolide Resistance?

Authors:  John R. Lonks
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

Review 9.  Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.

Authors:  Jack B Anon; Michael R Jacobs; Michael D Poole; Paul G Ambrose; Mark S Benninger; James A Hadley; William A Craig
Journal:  Otolaryngol Head Neck Surg       Date:  2004-01       Impact factor: 3.497

10.  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.

Authors:  Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.